Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 367

1.

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators.

Am Heart J. 2006 Oct;152(4):627-35.

PMID:
16996826
[PubMed - indexed for MEDLINE]
2.

Critical review of prasugrel for formulary decision makers.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2009 May;15(4):335-43. Review.

PMID:
19422273
[PubMed - indexed for MEDLINE]
Free Article
3.

Review of prasugrel for the secondary prevention of atherothrombosis.

Spinler SA, Rees C.

J Manag Care Pharm. 2009 Jun;15(5):383-95. Review.

PMID:
19496635
[PubMed - indexed for MEDLINE]
Free Article
4.

Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.

Thomas D, Giugliano RP.

Crit Pathw Cardiol. 2009 Mar;8(1):12-9. doi: 10.1097/HPC.0b013e318196bb46. Review.

PMID:
19258833
[PubMed - indexed for MEDLINE]
5.

Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?

Wiviott SD.

Cardiol Clin. 2008 Nov;26(4):629-37. doi: 10.1016/j.ccl.2008.07.003. Review.

PMID:
18929236
[PubMed - indexed for MEDLINE]
6.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
[PubMed - indexed for MEDLINE]
7.

Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Duggan ST, Keating GM.

Drugs. 2009 Aug 20;69(12):1707-26. doi: 10.2165/10484190-000000000-00000. Review.

PMID:
19678718
[PubMed - indexed for MEDLINE]
8.

Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.

Baker WL, White CM.

Am J Cardiovasc Drugs. 2009;9(4):213-29. doi: 10.2165/1131209-000000000-00000. Review.

PMID:
19655817
[PubMed - indexed for MEDLINE]
9.

Optimizing platelet P2Y12 inhibition for patients undergoing PCI.

Steinhubl S, Roe MT.

Cardiovasc Drug Rev. 2007 Summer;25(2):188-203. Review. Erratum in: Cardiovasc Drug Rev. 2007 Autumn;25(3):299.

PMID:
17614940
[PubMed - indexed for MEDLINE]
10.

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?

Silva MA, Donovan JL, Gandhi PJ, Volturo GA.

Vasc Health Risk Manag. 2006;2(1):39-48. Review.

PMID:
17319468
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.

Toth PP.

Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955. Review.

PMID:
19179814
[PubMed - indexed for MEDLINE]
12.

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD.

Lancet. 2009 Sep 19;374(9694):989-97. doi: 10.1016/S0140-6736(09)61525-7. Epub 2009 Aug 31. Review.

PMID:
19726078
[PubMed - indexed for MEDLINE]
13.

Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.

Martin MT, Spinler SA, Nutescu EA.

Clin Ther. 2011 Apr;33(4):425-42. doi: 10.1016/j.clinthera.2011.04.007. Review.

PMID:
21635989
[PubMed - indexed for MEDLINE]
14.

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(40):iii-iv, xv-xvi, 1-141. Review.

PMID:
15461878
[PubMed - indexed for MEDLINE]
Free Article
15.

Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Capranzano P, Ferreiro JL, Angiolillo DJ.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):361-9. doi: 10.1586/erc.09.4. Review.

PMID:
19379060
[PubMed - indexed for MEDLINE]
16.

[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].

Abbate R, Crea F, De Servi S, Filippi E, Gensini GF, Golinos P, Savonitto S.

G Ital Cardiol (Rome). 2010 Feb;11(2):127-37. Review. Italian.

PMID:
20408476
[PubMed - indexed for MEDLINE]
17.

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Norgard NB, Abu-Fadel M.

Vasc Health Risk Manag. 2009;5:873-82. Epub 2009 Nov 2. Review.

PMID:
19898643
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Prasugrel: Clinical development and therapeutic application.

Guerra DR, Tcheng JE.

Adv Ther. 2009 Nov;26(11):999-1011. doi: 10.1007/s12325-009-0081-y. Epub 2009 Dec 17. Review.

PMID:
20020231
[PubMed - indexed for MEDLINE]
19.

Thienopyridine antiplatelet agents: focus on prasugrel.

Freeman MK.

Consult Pharm. 2010 Apr;25(4):241-57. doi: 10.4140/TCP.n.2010.241. Review.

PMID:
20511177
[PubMed - indexed for MEDLINE]
20.

Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.

Tcheng JE, Mackay SM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):83-91. doi: 10.2165/11594600-000000000-00000. Review.

PMID:
22316323
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk